Magnus Axelson

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: JOURNAL OF HEMATOLOGY AND ONCOLOGY. 2019;12(1):80
Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK⁺ T-cell lymphoma
George B; George SK; Shi W; Haque A; Shi P; Eskandari G; Axelson M; Larsson O; Kaseb AO; Amin HM
Article: ONCOTARGET. 2017;8(46):81501-81510
Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response
Aiken R; Axelson M; Harmenberg J; Klockare M; Larsson O; Wassberg C
Article: SCANDINAVIAN JOURNAL OF CLINICAL AND LABORATORY INVESTIGATION. 2017;77(3):184-189
Circulating androgens and SHBG during the normal menstrual cycle in two ethnic populations
Rezaii T; Gustafsson TP; Axelson M; Zamani L; Ernberg M; Hirschberg AL; Carlstrom KAM
Article: ACTA ONCOLOGICA. 2016;55(2):140-148
A novel oral insulin-like growth factor-1 receptor pathway modulator and its implications for patients with non-small cell lung carcinoma: A phase I clinical trial
Ekman S; Harmenberg J; Frodin J-E; Bergstrom S; Wassberg C; Eksborg S; Larsson O; Axelson M; Jerling M; Abrahmsen L; Hedlund A; Alvfors C; Stahl B; Bergqvist M
Article: MEDICAL ONCOLOGY. 2015;32(7):188
Picropodophyllin inhibits proliferation and survival of diffuse large B-cell lymphoma cells
Stromberg T; Feng X; Delforoush M; Berglund M; Lin Y; Axelson M; Larsson O; Georgii-Hemming P; Lennartsson J; Enblad G
Article: ONCOTARGET. 2014;5(22):11193-11208
The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic
Bieghs L; Lub S; Fostier K; Maes K; Van Valckenborgh E; Menu E; Johnsen HE; Overgaard MT; Larsson O; Axelson M; Nyegaard M; Schots R; Jernberg-Wiklund H; Vanderkerken K; De Bruyne E
Article: ONCOTARGET. 2014;5(18):8379-8392
Picropodophyllin causes mitotic arrest and catastrophe by depolymerizing microtubules via Insulin-like growth factor-1 receptor-independent mechanism
Waraky A; Akopyan K; Parrow V; Stroemberg T; Axelson M; Abrahmsen L; Lindqvist A; Larsson O; Aleem E
Article: ORGANIC PROCESS RESEARCH AND DEVELOPMENT. 2014;18(5):643-645
Facile Production Scale Synthesis of (S)-Taniguchi Lactone: A Precious Building-Block
von Kieseritzky F; Wang Y; Axelson M
Article: CLINICAL ENDOCRINOLOGY. 2013;78(5):700-705
Cortisol metabolism after weight loss: associations with 11 β-HSD type 1 and markers of obesity in women
Rask E; Simonyte K; Lonn L; Axelson M
Article: CLINICAL CANCER RESEARCH. 2012;18(8):2230-2239
The HDAC Inhibitor LBH589 Enhances the Antimyeloma Effects of the IGF-1RTK Inhibitor Picropodophyllin
Lemaire M; Fristedt C; Agarwal P; Menu E; Van Valckenborgh E; De Bruyne E; Osterborg A; Atadja P; Larsson O; Axelson M; Van Camp B; Jernberg-Wiklund H; Vanderkerken K
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2012;40(4):1251-1258
Multiple antitumor effects of picropodophyllin in colon carcinoma cell lines: Clinical implications
Feng X; Aleem E; Lin Y; Axelson M; Larsson O; Stromberg T
Article: PLOS ONE. 2011;6(3):e14757
Molecular Characterization of Acquired Tolerance of Tumor Cells to Picropodophyllin (PPP)
Hashemi J; Worrall C; Vasilcanu D; Fryknas M; Sulaiman L; Karimi M; Weng W-H; Lui W-O; Rudduck C; Axelson M; Jernberg-Wiklund H; Girnita L; Larsson O; Larsson C
Article: JOURNAL OF CHROMATOGRAPHY B: ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES. 2011;879(5-6):326-334
Determination of picropodophyllin and its isomer podophyllotoxin in human serum samples with electrospray ionization of hexylamine adducts by liquid chromatography-tandem mass spectrometry
Ronquist-Nii Y; Eksborg S; Axelson M; Harmenberg J; Beck O
Article: AMERICAN JOURNAL OF CANCER RESEARCH. 2011;1(3):356-361
Potent inhibitory effect of the cyclolignan picropodophyllin (PPP) on human adrenocortical carcinoma cells proliferation
Doghman M; Axelson M; Lalli E
Article: FERTILITY AND STERILITY. 2010;93(8):2621-2626
Selective insulin-like growth factor-I antagonist inhibits mouse embryo development in a dose-dependent manner
Inzunza J; Danielsson O; Lalitkumar PG; Larsson O; Axelson M; Tohonen V; Danielsson KG; Stavreus-Evers A
Article: NEURO-ONCOLOGY. 2010;12(1):19-27
Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma
Yin S; Girnita A; Stromberg T; Khan Z; Andersson S; Zheng H; Ericsson C; Axelson M; Nister M; Larsson O; Ekstrom TJ; Girnita L
Article: EXPERIMENTAL CELL RESEARCH. 2009;315(8):1458-1467
Aberrant intracellular IGF-1R β-subunit makes receptor knockout cells (IGF1R^-/-) susceptible to oncogenic transformation
Natalishvili N; Axelson M; Girnita L; Larsson O; Vasilcanu D
Article: ACTA OPHTHALMOLOGICA. 2008;86 Thesis 4:42-49
Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor.
Economou MA; Wu J; Vasilcanu D; Rosengren L; All-Ericsson C; van der Ploeg I; Menu E; Girnita L; Axelson M; Larsson O; Seregard S; Kvanta A
Article: ACTA OPHTHALMOLOGICA. 2008;86 Thesis 4:35-41
Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma.
Economou MA; Andersson S; Vasilcanu D; All-Ericsson C; Menu E; Girnita A; Girnita L; Axelson M; Seregard S; Larsson O
Article: ACTA OPHTHALMOLOGICA. 2008;86 Thesis 4:26-34
The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells.
Girnita A; All-Ericsson C; Economou MA; Aström K; Axelson M; Seregard S; Larsson O; Girnita L
Article: INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE. 2008;49(6):2620-2626
Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor
Economou MA; Wu J; Vasilcanu D; Rosengren L; All-Ericsson C; van der Ploeg I; Menu E; Girnita L; Axelson M; Larsson O; Seregard S; Kvanta A
Article: INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE. 2008;49(6):2337-2342
Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma
Economou MA; Andersson S; Vasilcanu D; All-Ericsson C; Menu E; Girnita A; Girnita L; Axelson M; Seregard S; Larsson O
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2008;368(3):793-800
Differential roles of SS18-SSX fusion gene and insulin-like growth factor-1 receptor in synovial sarcoma cell growth
Toernkvist M; Natalishvili N; Xie Y; Girnita A; D'Arcy P; Brodin B; Axelson M; Girnita L
Article: THE FEBS JOURNAL. 2008;275(8):1778-1789
CYP7B1-mediated metabolism of dehydroepiandrosterone and 5α-androstane-3β,17β-diol -: potential role(s) for estrogen signaling
Pettersson H; Holmberg L; Axelson M; Norlin M
Article: ONCOGENE. 2008;27(11):1629-1638
Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor:: potential mechanistic involvement of Mdm2 and β-arrestin1
Vasilcanu R; Vasilcanu D; Rosengren L; Natalishvili N; Sehat B; Yin S; Girnita A; Axelson M; Girnita L; Larsson O
Article: MOLECULAR PHARMACOLOGY. 2008;73(3):930-939
Insulin-like growth factor type-I receptor-dependent phosphorylation of extracellular signal-regulated kinase 1/2 but not Akt (protein kinase B) can be induced by picropodophyllin
Vasilcanu R; Vasilcanu D; Sehat B; Yin S; Girnita A; Axelson M; Girnita L
Article: INTERNATIONAL JOURNAL OF CANCER. 2007;121(8):1857-1861
Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: Beneficial effects on tumor growth, angiogenesis, bone disease and survival
Menu E; Jernberg-Wiklund H; De Raeve H; De Leenheer E; Coulton L; Gallagher O; Van Valckenborgh E; Larsson O; Axelson M; Nilsson K; Van Camp B; Croucher P; Vanderkerken K
Article: JOURNAL OF VASCULAR SURGERY. 2007;46(1):108-115
The cyclolignan picropodophyllin attenuates intimal hyperplasia after rat carotid balloon injury by blocking insulin-like growth factor-1 receptor signaling
Razuvaev A; Henderson B; Girnita L; Larsson O; Axelson M; Hedin U; Roy J
Article: JOURNAL OF LIPID RESEARCH. 2007;48(4):944-951
Novel route for elimination of brain oxysterols across the blood-brain barrier:: conversion into 7α-hydroxy-3-oxo-4-cholestenoic acid
Meaney S; Heverin M; Panzenboeck U; Ekstrom L; Axelsson M; Andersson U; Diczfalusy U; Pikuleva I; Wahren J; Sattler W; Bjorkhem I
Article: JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. 2007;320(2):695-705
Role of pituitary hormones on 17α-ethinylestradiol-induced cholestasis in rat
Henriquez-Hernandez LA; Flores-Morales A; Santana-Farre R; Axelson M; Nilsson P; Norstedt G; Fernandez-Perez L
Article: ENDOCRINOLOGY. 2007;148(1):128-139
Insulin-like growth factor-I is an important antiapoptotic factor for rat Leydig cells during postnatal development
Colon E; Zaman F; Axelson M; Larsson O; Carlsson-Skwirut C; Svechnikov KV; Soder O
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2006;347(4):1059-1066
IGF-1R tyrosine kinase expression and dependency in clones of IGF-1R knockout cells (R-)
Rosengren L; Vasilcanu D; Vasilcanu R; Fickenscher S; Sehat B; Natalishvili N; Naughton S; Yin S; Girnita A; Girnita L; Axelson M; Larsson O
Article: CLINICAL CANCER RESEARCH. 2006;12(15):4506-4514
Hypoxia-inducible factor-1α- and hypoxia-inducible factor-2α are expressed in Kaposi sarcoma and modulated by insulin-like growth factor-I
Catrina S-B; Botusan IR; Rantanen A; Catrina AI; Pyakurel P; Savu O; Axelson M; Biberfeld P; Poellinger L; Brismar K
Article: ONCOGENE. 2006;25(22):3186-3195
The insulin-like growth factor-1 receptor inhibitor PPP produces only very limitedresistance in tumor cells exposed to long-term selection
Vasilcanu D; Weng W-H; Girnita A; Lui W-O; Vasilcanu R; Axelson M; Larsson O; Larsson C; Girnita L
Article: CLINICAL CANCER RESEARCH. 2006;12(4):1383-1391
The insulin-like growth factor-1 receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells
Girnita A; All-Ericsson C; Economou MA; Åström K; Axelson M; Seregard S; Larsson O; Girnita L
Article: BLOOD. 2006;107(2):655-660
Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model
Menu E; Jernberg-Wiklund H; Stromberg T; De Raeve H; Girnita L; Larsson O; Axelson M; Asosingh K; Nilsson K; Van Camp B; Vanderkerken K
Article: BLOOD. 2006;107(2):669-678
IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G₂/M-phase accumulation and apoptosis in multiple myeloma cells
Strömberg T; Ekman S; Girnita L; Dimberg LY; Larsson O; Axelson M; Lennartsson J; Hellman U; Carlson K; Österborg A; Vanderkerken K; Nilsson K; Jernberg-Wiklund H
Article: BLOOD PRESSURE. 2006;15(3):169-172
The liquorice effect on the RAAS differs between the genders
Sigurjonsdottir HA; Axelson M; Johannsson G; Manhem K; Nystrom E; Wallerstedt S
Article: HORMONE RESEARCH IN PAEDIATRICS. 2006;65(2):106-110
Liquorice in moderate doses does not affect sex steroid hormones of biological importance although the effect differs between the genders
Sigurjonsdottir HA; Axelson M; Johannsson G; Manhem K; Nyström E; Wallerstedt S
Article: EUROPEAN JOURNAL OF ENDOCRINOLOGY (EJE). 2006;154(1):69-74
GH effect on enzyme activity of 11βHSD in abdominal obesity is dependent on treatment duration
Sigurjónsdóttir HA; Koranyi J; Axelson M; Bengtsson B; Johannsson G
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2005;280(31):28324-28331
A novel polymorphic cytochrome P450 formed by splicing of CYP3A7 and the pseudogene CYP3AP1
Rodriguez-Antona C; Axelson M; Otter C; Rane A; Ingelman-Sundberg M
Article: CLINICAL CANCER RESEARCH. 2005;11(13):4674-4680
Expression and growth dependency of the insulin-like growth factor I receptor in craniopharyngioma cells:: A novel therapeutic approach
Ulfarsson E; Karström A; Yin SC; Girnita A; Vasilcanu D; Thoren M; Kratz G; Hillman J; Axelson M; Larsson O; Girnita L
Article: BRITISH JOURNAL OF CANCER. 2005;92(8):1467-1474
Insulin-like growth factor-I receptor activity is essential for Kaposi's sarcoma growth and survival
Catrina SB; Lewitt M; Massambu C; Dricu A; Grünler J; Axelson M; Biberfeld P; Brismar K
Article: ONCOGENE. 2004;23(47):7854-7862
The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway
Vasilcanu D; Girnita A; Girnita L; Vasilcanu R; Axelson M; Larsson O
Article: BRITISH JOURNAL OF NUTRITION. 2004;91(6):959-969
Lipoprotein metabolism in patients with anorexia nervosa:: a case-control study investigating the mechanisms leading to hypercholesterolaemia
Weinbrenner T; Züger M; Jacoby GE; Herpertz S; Liedtke R; Sudhop T; Gouni-Berthold I; Axelson M; Berthold HK
Article: INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS. 2004;42(6):307-313
Influence of rifampin on serum markers of cholesterol and bile acid synthesis in men
Lütjohann D; Hahn C; Prange W; Sudhop T; Axelson M; Sauerbruch T; von Bergmann K; Reichel C
Article: CANCER RESEARCH. 2004;64(1):236-242
Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth
Girnita A; Girnita L; del Prete F; Bartolazzi A; Larsson O; Axelson M
Article: HEPATOLOGY. 2003;38(4):930-938
Feedback regulation of bile acid synthesis in primary human hepatocytes:: Evidence that CDCA is the strongest inhibitor
Ellis E; Axelson M; Abrahamsson A; Eggertsen G; Thörne A; Nowak G; Ericzon BG; Björkhem I; Einarsson C
Article: STEROIDS. 2003;68(7-8):595-601
On the origin of the cholestenoic acids in human circulation
Meaney S; Babiker A; Lütjohann D; Diczfalusy U; Axelson M; Bjrökhem I
Article: JOURNAL OF HUMAN HYPERTENSION. 2003;17(2):125-131
Subjects with essential hypertension are more sensitive to the inhibition of 11 β-HSD by liquorice
Sigurjonsdottir HA; Manhem K; Axelson M; Wallerstedt S
Article: CANCER LETTERS. 2001;170(2):169-175
Cholesterol catabolism in patients with acute myelogenous leukemia and hypocholesterolemia: suppressed levels of a circulating marker for bile acid synthesis
Tatidis L; Vitols S; Gruber A; Paul C; Axelson M
Article: HEPATOLOGY. 2001;33(5):1189-1193
Effects of treatment with deoxycholic acid and chenodeoxycholic acid on the hepatic synthesis of cholesterol and bile acids in healthy subjects
Einarsson C; Hillebrant CG; Axelson M
Article: WORLD JOURNAL OF GASTROENTEROLOGY. 2000;6(4):522-525
Bile acid formation in primary human hepatocytes
Einarsson C; Ellis E; Abrahamsson A; Ericzon BG; Björkhem I; Axelson M
Article: HEPATOLOGY. 2000;31(6):1305-1312
Bile acid synthesis in cultured human hepatocytes:: Support for an alternative biosynthetic pathway to cholic acid
Axelson M; Ellis E; Mörk B; Garmark K; Abrahamsson A; Björkhem I; Ericzon BG; Einarsson C
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2000;29(2):89-94
Endocrine effects of the podophyllotoxine derivative drug CPH 82 (Reumacon®) in patients with rheumatoid arthritis
Carlström K; Hedin PJ; Jönsson L; Lerndal T; Lien J; Weitoft T; Axelson M
Article: JOURNAL OF INTERNAL MEDICINE. 1999;246(4):399-407
Deoxycholic acid treatment in patients with cholesterol gallstones:: failure to detect a suppression of cholesterol 7α-hydroxylase activity
Hillebrant CG; Nyberg B; Angelin B; Axelson M; Björkhem I; Rudling M; Einarsson C
Article: EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 1999;29(5):404-412
Effect of inhibiting HMG-CoA reductase on 7α-hydroxy-4-cholesten-3-one, a marker of bile acid synthesis:: contrasting findings in patients with and without prior up-regulation of the latter pathway
Naoumova RP; O'Neill FH; Dunn S; Neuwirth CKY; Taylor GW; Axelson M; Thompson GR
Article: JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM (JCEM). 1999;84(4):1210-1213
Failure of cortisone acetate treatment in congenital adrenal hyperplasia because of defective 11β-hydroxysteroid dehydrogenase reductase activity
Nordenström A; Marcus C; Axelson M; Wedell A; Ritzén EM
Article: BIOCHIMICA ET BIOPHYSICA ACTA: INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND BIOPHYSICS. 1998;1394(2-3):153-157
The level of 7-dehydrocholesterol in plasma reflects the activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase in the human liver
Axelson M; Angelin B; Hillebrant CG; Reihner E; Einarsson C
Article: EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 1998;28(4):324-328
Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients
Hillebrant CG; Axelson M; Björkhem I; Wang FH; Nyberg B; Einarsson C
Article: HEPATOLOGY. 1997;26(6):1573-1579
Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: Effect of ursodeoxycholic acid therapy
Meng LJ; Reyes H; Axelson M; Palma J; Hernandez I; Ribalta J; Sjovall J
Article: JOURNAL OF HEPATOLOGY. 1997;27(1):150-155
Circulating markers for biosynthesis of cholesterol and bile acids are not depressed in asymptomatic gallstone subjects
Muhrbeck O; Wang FH; Bjorkhem I; Axelson M; Einarsson K
Article: EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 1997;27(5):387-391
The effect of vitamin C in high doses on plasma and biliary lipid composition in patients with cholesterol gallstones: Prolongation of the nucleation time
Gustafsson U; Wang FH; Axelson M; Kallner A; Sahlin S; Einarsson K
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 1996;271(22):12724-12736
27-Hydroxylated low density lipoprotein (LDL) cholesterol can be converted to 7 alpha,27-dihydroxy-4-cholesten-3-one (cytosterone) before suppressing cholesterol production in normal human fibroblasts - Evidence that an altered metabolism of LDL cholesterol can underlie a defective feedback control in malignant cells
Axelson M; Larsson O
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 1995;270(25):15102-15110
LOW-DENSITY-LIPOPROTEIN (LDL) CHOLESTEROL IS CONVERTED TO 27-HYDROXYCHOLESTEROL IN HUMAN FIBROBLASTS - EVIDENCE THAT 27-HYDROXYCHOLESTEROL CAN BE AN IMPORTANT INTRACELLULAR MEDIATOR BETWEEN LDL AND THE SUPPRESSION OF CHOLESTEROL PRODUCTION
AXELSON M; LARSSON O
Article: JOURNAL OF LIPID RESEARCH. 1995;36(2):290-298
STRUCTURAL SPECIFICITY IN THE SUPPRESSION OF HMG-COA REDUCTASE IN HUMAN FIBROBLASTS BY INTERMEDIATES IN BILE-ACID BIOSYNTHESIS
AXELSON M; LARSSON O; ZHANG J; SHODA J; SJOVALL J
Visa fler

Alla övriga publikationer

Corrigendum: JOURNAL OF CHROMATOGRAPHY B: ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES. 2012;889:148
Determination of picropodophyllin and its isomer podophyllotoxin in human serum samples with electrospray ionization of hexylamine adducts by liquid chromatography-tandem mass spectrometry (vol 879, pg 326, 2011)
Ronquist-Nii Y; Eksborg S; Axelson M; Harmenberg J; Ekman S; Bergqvist M; Beck O
Meeting abstract: JOURNAL OF VASCULAR SURGERY. 2010;51:72S-73S
A Specific Inhibitor of IGF-1 Receptor - Picropodophyllin Can Suppress Atheroma Progression and Has a Stabilizing Effect on Atherosclerotic Lesions in ApoE Deficient Mice
Razuvaev A; Larsson O; Axelson M; Hedin U; Roy J
Letter: CANCER RESEARCH. 2007;67(6):2899-2900
Cyclolignans as inhibitors of the insulin-like growth factor-I receptor
Larsson O; Axelson M
Meeting abstract: BLOOD. 2004;104(11):184A-185A
Targeting the insulin-like growth factor-i receptor (IGF-IR) in multiple myeloma cells using selective IGF-IR tyrosine kinase inhibitors.
Stromberg T; Ekman S; Girnita L; Lennartsson J; Hellman U; Carlson K; Osterborg A; Vanderkerken K; Axelson M; Larsson O; Jernberg-Wiklund H
Meeting abstract: JOURNAL OF AMERICAN ACADEMY OF DERMATOLOGY. 2004;50(3):P117
Possible use of flavonoids as cell growth inhibitors in malignant melanoma
Girnita A; Girnita L; Axelson M; Larsson O
Letter: JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM (JCEM). 2001;86(3):1426-1427
Defective 11β-HSD reductase activity in a patient with congenital adrenal hyperplasia
Nordenstrom A; Marcus C; Axelson M; Wedell A; Ritzén M
Meeting abstract: GASTROENTEROLOGY. 2000;118(4):A450
The effects of treatment with chenodeoxycholic acid and deoxycholic acid on cholesterol and bile acid synthesis in healthy subjects.
Hillebrant CG; Axelsson M; Einarsson C

Anställningar

Anknuten till Forskning, Molekylär medicin och kirurgi, Karolinska Institutet, 2022-2025

Examina och utbildning

Docent, Professor i klinisk kemi (adj./aff.) sedan 2000-05-01., Karolinska Institutet, 1980

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI